source
- Novartis’ BTK inhibitor remibrutinib cuts MS relapse rates in Phase 3, setting up FDA filingNovartis reported that its BTK inhibitor remibrutinib, already approved for chronic spontaneous urticaria, lowered annualized relapse rates in two Phase 3 studies of relapsing multiple sclerosis wh…
- Teva's anti-IL-15 antibody meets primary endpoint in phase 2a celiac disease trialTeva Pharmaceuticals reported that its anti‑interleukin‑15 antibody, TEV‑408, achieved the primary endpoint in a phase 2a study of 50 adults with celiac disease. Participants received a single dose…